Analysis and identification of potential type II helper T cell (Th2)-Related key genes and therapeutic agents for...

Area of Science:

• Immunology
• Virology
• Genomics

Background:

• The COVID-19 pandemic presents a significant global health challenge with no currently effective antiviral drugs.
• Understanding the host's transcriptomic response, particularly involving T helper 2 (Th2) cells, is crucial for identifying therapeutic targets against SARS-CoV-2.

Purpose of the Study:

• To identify key genes associated with Th2 cell responses in COVID-19 patients.
• To explore potential therapeutic targets and drug candidates for COVID-19 treatment based on transcriptomic data.

Main Methods:

• Analysis of five COVID-19-related Gene Expression Omnibus (GEO) datasets using xCell and weighted gene co-expression network analysis (WGCNA).
• Intersection of co-expression modules with differentially expressed genes (DEGs) to identify shared genes.
• Gene Ontology (GO) and KEGG pathway enrichment analyses were performed.
• Identification of drug candidates using the cMAP database and molecular docking.

Main Results:

• 648 shared genes were identified, significantly enriched in pathways related to cell proliferation, differentiation, and immune responses to viral infection, including viral life cycle regulation.
• Three key genes—CCNB1, BUB1, and UBE2C—were highlighted for their potential role in COVID-19 pathogenesis associated with Th2 cells.
• Eleven potential drug candidates were identified that could down-regulate these key genes, showing strong binding affinities.

Conclusions:

• CCNB1, BUB1, and UBE2C are identified as critical genes in COVID-19 pathogenesis linked to Th2 cell activity.
• These genes represent promising therapeutic targets for developing new COVID-19 treatments.
• The identified drug candidates warrant further investigation for their efficacy in down-regulating these target genes.